comparemela.com
Home
Live Updates
Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection : comparemela.com
Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection
SHANGHAI, China, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated
Related Keywords
China ,
United States ,
Shanghai ,
Chinese ,
Datao Liu ,
Junshi Bioscience ,
Junshi Biosciences ,
Zhi Li ,
Mabwell Biosciences ,
Mabwell Bioscience ,
Ir Team ,
Pr Team ,
National Medical Products Administration ,
Mabwell Shanghai Bioscience Co Ltd ,
Shanghai Junshi Biosciences Co Ltd ,
Healthy China Innitiative ,
Plaque Psoriasis ,
Chinese Academy ,
Emergency Use Authorizations ,
Junshi ,
Iosciences ,
Nnounces ,
Approval ,
Supplemental ,
Application ,
Dditional ,
Indications ,
Adalimumab ,
Injection ,
comparemela.com © 2020. All Rights Reserved.